After blueprinting R&D hub, AbbVie dishes out $105M for CD39 pact with Tizona's new CEO from Roche
With the $10 billion Rova-T program seemingly headed toward the cliff, AbbVie is turning to an early-stage collaboration for a longer shot at cancer drug success.
For its latest foray into the tumor microenvironment, AbbVie has partnered up Tizona Therapeutics, an MPM-founded biotech located just up the road from the oncology R&D hub that AbbVie is building at Oyster Point, South San Francisco.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.